Equillium

Equillium Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Equillium (EQ) as of Nov 3, 2026 is 1.31. In the previous year, Net Debt to Free Cash Flow Ratio was 1.18 — a change of 11.10% (higher).

Net Debt/FCF

1.31

YoY

11.10%

Last updated:

Net Debt to Free Cash Flow Ratio of Equillium is 2025 1.31 . Net Debt to Free Cash Flow Ratio of Equillium was 2024 1.18 . It decreases by 11.10% higher compared to the previous year.

The Equillium Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2018
8.72 USD
Jan 1, 2019
1.89 USD
Jan 1, 2020
2.91 USD
Jan 1, 2021
2.19 USD
Jan 1, 2022
6.89 USD
Jan 1, 2023
1.87 USD
Jan 1, 2024
1.18 USD
Jan 1, 2025
1.31 USD
The Equillium Net Debt/FCF history
YEARNet Debt/FCFYoY
1.31+11.10%
1.18-36.89%
1.87-72.83%
6.89+213.85%
2.19-24.56%
2.91+54.10%
1.89-78.34%
8.72-705.56%
-1.44—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Equillium Stock analysis

What does Equillium do? Equillium Inc is an emerging biotechnology company specializing in the research and development of therapies for the treatment of inflammatory and autoimmune diseases. The company was founded in 2017 by a group of experienced biotech entrepreneurs who aim to develop innovative and effective treatment methods to improve patients' quality of life. Equillium's business model focuses on the discovery and development of new therapies based on the modulation of the CD6 signaling pathway, a central regulator of the immune system. Equillium's technology aims to modulate the immune system to suppress an inflammatory response associated with autoimmune and other inflammatory diseases. The company collaborates closely with leading university research laboratories and experts in the field to develop effective therapies. Equillium targets a wide range of disease areas, including autoimmune diseases such as lupus, psoriasis, and Crohn's disease. The company has also developed a program to treat COVID-19, aiming to reduce the immune-mediated inflammatory response associated with severe cases of COVID-19. Equillium's product portfolio includes EQ001, a monoclonal antibody used for the treatment of lupus and other autoimmune diseases. EQ001 blocks the CD6 signaling pathway, thereby reducing inflammatory responses that attack healthy tissues in the body. The company is also working on developing a novel platform technology to explore additional therapy options based on the CD6 signaling pathway. Equillium has a strong funding base and is supported by some of the most renowned biotech investors. The company has a comprehensive pipeline of potential therapies that are intended to address a variety of indications in the future. Overall, Equillium's advanced biotechnological research and development have contributed to the discovery of new and effective ways to treat inflammatory and autoimmune diseases. The company is well-positioned to expand in this area of medicine and improve therapy options for patients worldwide. Equillium is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Equillium stock

Net Debt to Free Cash Flow Ratio of Equillium is 1.31 in 2025.

Net Debt to Free Cash Flow Ratio of Equillium changed from 1.18 to 1.31, representing a 11.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Equillium since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Equillium with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Equillium

All Key Metrics — Equillium